A phase II pilot investigation of the relationship of short term Depo-Provera (medroxyprogesterone acetate) exposure to the morphologic biochemical and molecular changes in primary endometroid adenocarcinoma of the uterine corpus.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Medroxyprogesterone (Primary)
- Indications Uterine cancer
- Focus Therapeutic Use
Most Recent Events
- 11 Apr 2016 Biomarkers information updated
- 16 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.